A Phase 4 interventional study of prazosin in Posttraumatic Stress Disorder, Metabolic Syndrome and Insulin Resistance, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing prazosin in Stress Disorders, Post-Traumatic — 1 open to participants now, 2 under way, 1 of them phase 3. Prazosin · Stress Disorders, Post-Traumatic.
Among the 22 studies testing prazosin in Stress Disorders, Post-Traumatic, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 4, and was the 22nd registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →1 of the 22 studies testing prazosin in Stress Disorders, Post-Traumatic is open now, in 1 country.
By country, each count listing its studies:
Prazosin: first FDA approval 1976 (MINIPRESS). What it is approved for, and how studies give it, is on its page →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 40 across the 21 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 22 have an industry lead sponsor. The 10 most frequent:
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development: 56 open now, 65 under way, 4 of them phase 3. Of 194 finished, 167 (86%) have results posted.
Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 150th largest by planned enrollment of the 246 interventional ones that give a count, is one of 14 that started in 2027, is one of 14 in phase 4, reaches primary completion later than 62 of the 64 other live ones, and was the 261st registered.
VA Office of Research and Development’s Stress Disorders, Post-Traumatic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing prazosin in Stress Disorders, Post-Traumatic, from their registry updates:
Among VA Office of Research and Development’s 263 in Stress Disorders, Post-Traumatic:
This tab as a report to print or save as PDF → With an account.
KEY INFORMATION: The purpose of this study is to understand how insulin resistance (how your body processes sugar) and PTSD might be related. The goal is to improve the health of Veterans in three ways:
Background and Study Objective: Post-traumatic stress disorder (PTSD) affects as many as 15% of Veterans following deployment and is associated with high rates of medical comorbidities linked to insulin resistance (IR), which is present in over half of people with PTSD. PTSD severity is prospectively associated with increased risk of both worsening IR severity and new-onset type 2 diabetes mellitus, leading to premature mortality. Biological effects of trauma exposure are linked to downstream disruption of both brain and metabolic processes, with mounting evidence that trauma-related mechanisms leading to IR may be biologically distinct from that of IR in the general population. One potential mechanism linking trauma exposure to IR lies in studies of noradrenaline (NA) blockade, with 1 adrenoreceptor antagonists demonstrating benefit for insulin sensitivity in patients with IR and hypertension. While a substantial body of evidence supports a role for increased NA signaling in PTSD, the potential link between NA and IR in the context of PTSD deserves further investigation. This connection suggests that increased IR following trauma also has the potential to play a causal role in the generation of psychiatric symptoms, particularly depressive symptoms, with multiple studies suggesting a potential causal relationship of IR on depressive symptoms. Defining mechanistic links between mental health and metabolic disorders have important clinical implications that may improve our approach to treating both mental and physical health disorders in Veterans with a history of trauma.
Study Design and Methods: Interrelationships among NA signaling (estimated by standing systolic blood pressure), insulin sensitivity (estimated by Oral Glucose Insulin Sensitivity index), and mental health symptoms will be examined in a population of Veterans with current PTSD. The effect of prazosin-mediated 1 adrenoreceptor antagonism on insulin sensitivity will be assessed in an open label single-arm interventional clinical trial design, with exploratory analysis of a potential mediating effect of improved insulin sensitivity on improvement in depression. These measures will be used to test the hypotheses pertaining to Veterans with PTSD: (1) increased NA signaling and hyperarousal symptoms are associated with lowered insulin sensitivity, (2) lowered insulin sensitivity is associated with elevated depression symptoms, (3) insulin sensitivity will improve with prazosin-mediated 1 antagonism, and (4) improvement in insulin sensitivity will be associated with improvement in depressive symptoms in response to prazosin.
This work is expected to contribute to Veteran's health in three major ways: (1) The investigators are investigating biological mechanisms in Veterans with insulin resistance and PTSD. If this is successful, it will contribute to our understanding of why Veterans with PTSD are at increased risk for comorbid medical conditions related to insulin resistance such as diabetes. (2) The investigators are testing whether noradrenergic blockade with the medication prazosin, currently used to treat PTSD, affects insulin sensitivity in Veterans with PTSD. If successful, this would identify a specific biological pathway that could be targeted for development of novel pharmacotherapeutic approaches to insulin resistance and downstream diabetes in Veterans with PTSD. (3) Our results may also provide information about the effect of insulin sensitivity on depressive symptoms in PTSD. This information has potential to contribute to the development of new strategies for treating, or even preventing, depression in PTSD, as well as overall PTSD treatment strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigators will collect mental health and metabolic measures before and after prazosin treatment
Drug: prazosin
All participants will receive prazosin for 12 weeks according to a titration schedule informed by our prior studies, up to a minimum of 1mg in the morning and 3mg at night, up to a total daily dose of 16mg as tolerated. Higher doses may be considered as clinically appropriate.
Also known as: Minipress
Noradrenergic signaling and insulin sensitivity
Correlation between baseline noradrenergic signaling (standing systolic blood pressure) and insulin sensitivity (OGIS)
Time frame: 5 years
Insulin sensitivity change after prazosin
Change in insulin sensitivity (OGIS) in response to prazosin
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Dec 2031, 57 months later.
Of 30 non-industry phase 4 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 71. This study's planned 57 months is close to that.
Counting every sponsor, half of 31 studies reached it within 52 months; a quarter within 36 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prazosin
Stress Disorders, Post-Traumatic →
VA Office of Research and Development →